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The introduction of all-trans retinoic acid
(ATRA) and, more recently, arsenic triox-
ide (ATO) into the therapy of acute promy-
elocytic leukemia (APL) has revolution-
ized the management and outcome of this
disease. Several treatment strategies us-
ing these agents, usually in combination
with chemotherapy, but also without or
with minimal use of cytotoxic agents,
have provided excellent therapeutic re-
sults. Cure of APL patients, however, is
also dependent on peculiar aspects re-
lated to the management and supportive
measures that are crucial to counteract
life-threatening complications associ-
ated with the disease biology and molecu-
larly targeted treatment. The European
LeukemiaNet recently appointed an inter-
national panel of experts to develop
evidence- and expert opinion–based
guidelines on the diagnosis and manage-
ment of APL. Together with providing
current indications on genetic diagnosis,
modern risk-adapted front-line therapy
and salvage treatment, the review con-
tains specific recommendations for the
identification and management of most
important complications such as the
bleeding disorder, APL differentiation syn-
drome, QT prolongation and other ATRA-
and ATO-related toxicities, as well as for
molecular assessment of response to
treatment. Finally, the approach to spe-
cial situations is also discussed, includ-
ing management of APL in children, el-
derly patients, and pregnant women.
(Blood. 2009;113:1875-1891)
1. Introduction
Although the real incidence of acute promyelocytic leukemia
(APL) is unknown, it is a relatively rare hematologic malignancy.
The number of newly diagnosed cases per year in the United States
is estimated to be 600 to 800.1,2 One of the most striking features of
APL is its age-associated incidence rate. The disease is very
uncommon in children less than 10 years of age. Its incidence
increases steadily during the teen years, reaches a plateau during
early adulthood, and remains constant until it decreases after age
60 years.3 This is in marked contrast to other subtypes of acute
myeloid leukemia (AML), where there is a steady rise to age
55 years, after which there is an exponential increase. There is also
a suggestion in the literature that APL arising as a complication of
previous exposure to chemotherapy (particularly drugs targeting
topoisomerase II) or radiotherapy is becoming more prevalent,
particularly in patients with a history of breast cancer.4-6 With
respect to the incidence of APL among ethnic groups, contradictory
data regarding a presumed higher incidence of APL in persons from
Mexico, Central and South America, Italy, and Spain have been
reported in the literature.2,7 Therefore, this epidemiologic issue is
still a matter of controversy and deserves additional investigation.
The introduction of all-trans retinoic acid (ATRA; tretinoin)
into the therapy of APL completely revolutionized the management
and outcome of this disease. This agent represents one of the most
spectacular advances in the treatment of human cancer, providing
the first paradigm of molecularly targeted treatment. After the
advent of ATRA, the introduction of arsenic trioxide (ATO),
probably the most biologically active single drug in APL, has
provided a valuable addition to the armamentarium and may have
contributed to further improvements in the clinical outcome of this
disease. Several treatment strategies using these agents, usually in
combination with chemotherapy, have provided excellent therapeu-
tic results with survival rates exceeding 70% in multicenter clinical
trials. Cure of patients with APL depends not only on the effective
use of combination therapy involving differentiating and classical
cytotoxic agents, but also, critically, upon supportive care measures
that take into particular account the biology of the disease and the
complications associated with molecularly targeted therapies. More-
over, it is important to consider diagnostic suspicion of APL as a
medical emergency (uncommon in AML) that requires several
specific and simultaneous actions, including immediate commence-
ment of ATRA therapy, prompt genetic diagnosis, and measures to
counteract the coagulopathy.
Although there are some recent exhaustive reviews addressing
the management of APL8-13 and national guidelines from the
United States and United Kingdom14,15 on the management of
AML that include some specific items on APL, no comprehensive
yet succinct guidelines focused on APL have been produced.
Therefore, the European LeukemiaNet appointed an international
panel of experts to develop evidence- and expert opinion–based
guidelines on the management of APL. The publication of guide-
lines for the management of challenging malignant diseases
provides an excellent tool to spread knowledge of the optimum
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treatment of a given disease, but it is particularly useful in APL for
some additional reasons: (1) APL is a rare disease and most patients
are treated in institutions with limited experience; (2) the excellent
outcome reported recently with current treatments may engender a
sense of safety and complacency that may lead to underestimation
of the importance of crucial aspects of APL management; and
(3) some issues related to the treatment of APL are not well known,
lack strong supporting data, and, therefore, involve the risk of
adopting erroneous practices, which although appropriate and
routinely used for the management of other AML subtypes are
inappropriate for management of APL.
2. Methods
2.1. Composition of the panel
The panel included 12 members with recognized clinical and
research expertise in APL, of whom 9 came from European Union
countries (France, Germany, Italy, Spain, United Kingdom, and
The Netherlands), 2 from the United States, and 1 from Japan.
2.2. Scope of the review
A computerized literature search of the PubMed, Cochrane, and
Medline databases in the English language was conducted using
the key words “acute promyelocytic leukemia” with subheadings
“anthracycline,” “all-trans retinoic acid,” “arsenic trioxide,” “reti-
noic acid/differentiation syndrome,” “pregnancy,” “disseminated
intravascular coagulation” (DIC), “stem cell transplantation,” and
“febrile neutropenia.” Relevant abstracts presented at the 2004,
2005, 2006, and 2007 meetings of the American Society of
Hematology and the American Society of Clinical Oncology were
also reviewed. The authors have substantial experience in the field.
The levels of evidence and grading of recommendations were those
defined in the “General Guidelines for Methodologies on Research
and Evaluation of Traditional Medicine,”16 which are based on
those of the US Agency for Healthcare Research and Quality,
formerly the Agency for Health Care Policy and Research
(Appendix).
3. Approach to the patient with suspected
APL
Although there is a general consensus on the need to confirm the
diagnosis of APL at the genetic level, both differentiation and
supportive therapy should be started before the results of genetic
tests are available. In the majority of cases the diagnosis is
suggested by the characteristic morphology of the leukemic
population,17,18 however, it is also important to consider the
possibility of APL should any suspicion be raised based on
immunophenotypic profile or presence of severe coagulopathy; in
all such cases ATRA should be commenced immediately and
continued until the diagnosis is confirmed or refuted at the genetic
level.
3.1. Rapid confirmation of genetic diagnosis
Because the efficacy of differentiation treatment based on retinoids
and/or arsenic derivatives is strictly dependent on the presence of
the PML/RARA fusion in leukemia cells, genetic confirmation of
this specific lesion is mandatory in all cases. Morphologic diagno-
sis of hypergranular (typical) APL is highly predictive of an
underlying PML/RARA rearrangement, and immunophenotyping
by multiparameter flow cytometry can improve the accuracy of
diagnosis,19,20 particularly in patients with morphologic features
evoking a microgranular (variant) subtype. However, patients with
morphologic and/or immunophenotypic features suggestive of
APL without the PML/RARA rearrangement, and vice versa, have
been described in the literature.21-23
3.1.1. Diagnostic workup and sample processing. Recommen-
dations for diagnostic workup are summarized in Table 1.
All patients should have a marrow aspirate. This may be omitted
only when the peripheral blast count is high and the patient is to be
considered for palliative treatment only. A trephine biopsy is
required only in the case of a dry marrow aspirate and where no
abnormal cells are present in the peripheral blood (PB) to allow a
morphologic and molecular diagnosis.
Morphologic studies require a Romanowsky-derived stain, such
as Wright, Wright-Giemsa, or May-Grunwald-Giemsa stains, usu-
ally complemented by myeloperoxidase or Sudan black B stain.
Immunophenotyping by multiparameter flow cytometry can in-
crease the accuracy of a morphologic suspicion of PML/RARA-
positive APL. Typically, PML/RARA-positive leukemia blasts show
immunophenotypic features similar to those of normal promyelo-
cytes (CD34/ heterogeneous, CD117/ dim, HLADR–/ dim,
CD13/, CD11b).19 However, unlike their normal counterpart,
PML/RAR-positive promyelocytes display abnormally low levels
of CD15 (CD15/ dim vs CD15).19,20 Blasts of the hypogranu-
lar variant form of APL (M3v) frequently coexpress the T lineage–
affiliated marker CD2 with myeloid markers CD13 and CD33.24-26
Confirmation of genetic diagnosis is mandatory and should be
performed, if possible, on leukemia cells from bone marrow (BM).
The identification of the APL-specific genetic lesion in leukemic
cells is feasible at chromosome, DNA, RNA, and protein levels
with the use of conventional karyotyping, fluorescence in situ
hybridization (FISH), reverse transcriptase polymerase chain reac-
tion (RT-PCR), or anti-PML monoclonal antibodies, respectively.
Each of these has advantages and disadvantages.
Karyotyping. Karyotyping on G-banded metaphases obtained
from BM samples is usually performed by conventional methods
on direct, 24-hour, and 48-hour cultures. Although highly specific,
cytogenetic analysis is expensive, very time-consuming, needs
good quality metaphases (lacking in up to 20%), and by definition
fails to detect cases where the PML-RARA fusion results from
cryptic rearrangements (false negatives). In addition, secondary
chromosomal abnormalities seem not to have significant prognostic
value in APL.27,28 However, cytogenetics is potentially useful in the
characterization of cases lacking the PML-RARA fusion. This
may facilitate identification of rarer molecular subtypes of APL
including those with t(11;17)(q23;q21), t(11;17)(q13;q21), and
t(5;17)(q35;q21), leading to PLZF-RARA,29 NuMA-RARA30 and
NPM1-RARA31 fusions, respectively, as well as others more
recently described.32-34
FISH analysis. FISH analysis of PML/RARA can be carried out
using standard methods and commercially available fluorescently
labeled probes. Although in some cases PB samples are suitable for
study (particularly when hyperleukocytosis is present at diagnosis),
FISH is preferably performed in BM samples. The protocol for
FISH detection of PML/RARA has been reported in detail by
Grimwade et al.35 This methodology is highly specific and sensi-
tive, and much less expensive and time-consuming than karyotyp-
ing. However, it is important to recognize the potential limitations
of some probe sets used for molecular diagnostics. In particular,
those that specifically detect the RARA-PML fusion gene on
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der(17) will not show fusion signals in the presence of nonrecipro-
cal rearrangements where RARA-PML is deleted or where PML-
RARA is formed as a result of an insertion. Small PML-RARA
insertions can also be missed by FISH when using very large
probes; in such cases it is more appropriate to use relatively small
cosmid probes.22 FISH provides no information about the isoform
of PML/RARA, which is required for molecular monitoring of
minimal residual disease. However, FISH can be useful in the
investigation of suspected APL cases that lack a PML-RARA
fusion, using RARA probes that span the breakpoint region to
investigate for evidence of a RARA rearrangement, facilitating the
identification of the fusion partner.
RT-PCR. RT-PCR analysis of PML-RARA is preferably carried
out on RNA extracted from BM samples, although the fusion
transcript is usually readily detectable in PB even in cases
presenting with leukopenia. Standardized RT-PCR assays for
detection of the PML-RARA fusion were established within the
Biomed-1 Concerted Action.36 RT-PCR probably provides the
“gold standard” approach for confirming a diagnosis of APL. In
addition to its high specificity and sensitivity, it is essential for
defining PML breakpoint location thereby establishing the target
for reliable monitoring of MRD. However, poor RNA yield (false
negative), contamination and artifacts (false positives), and the
relatively long turnaround time (2 days) are the main drawbacks
of this methodology. In addition, it is advisable that diagnostic and
monitoring samples be analyzed in reference laboratories by
well-trained personnel with considerable expertise in RT-PCR for
PML-RARA.
Immunostaining with anti-PML monoclonal antibodies on dry
smears of BM or PB (providing circulating blasts are present) is
helpful to achieve a rapid diagnosis. This technique is highly
specific for presence of an underlying PML-RAR fusion pro-
tein,37-40 indicated by a microspeckled staining pattern ( 30 nuclear
dots) in the nuclei of leukemic cells with the PML antibody, which
detects both PML-RAR and the normal PML protein. The test
will also be positive in those rare cases where atypical breakpoints
occur within the PML locus, which could potentially be missed by
standard PCR primers. In normal cells and blasts from other
subtypes of leukemia (including APL molecular variants, eg,
PLZF-RARA and NPM1-RARA) a wild-type PML staining pattern
is observed with discrete nuclear dots (typically 20/nucleus) that
relate to organelles known as PML nuclear bodies.22,23 Either
indirect immunofluorescence or immunohistochemistry may be
used. Results from the immunofluorescence assay can be achieved
in only 2 hours. In light of its very convenient cost-benefit ratio, the
assay is highly recommended for rapid confirmation of the
diagnosis of APL and effectively identifying patients with the
PML-RARA fusion, thereby predicting those likely to respond to
molecularly targeted therapy with ATRA or ATO. This test is
particularly valuable in small centers lacking access to a molecular
diagnostics laboratory and in cases in which RNA is not available
to confirm a diagnosis.
All of the aforementioned options are equally specific, but not
equally reliable, methods to confirm the genetic diagnosis of APL.
In particular, cytogenetics is much less efficient than the others. In
terms of rapidity, specificity, and sensitivity, FISH and immunostain-
ing with anti-PML monoclonal antibodies are highly efficient to
confirm the diagnosis of APL. However, these techniques should
not replace RT-PCR, which allows definition of the type of
PML-RARA isoform and the target for MRD evaluation.
Sample processing and banking. A specific recommendation
for sample banking of all AML cases at diagnosis has been made in
the revised criteria for AML diagnosis and outcome evaluation.41
The laboratory that will assume the responsibility for sample
Table 1. Diagnostic workup and supportive care
Recommendation Level of evidence Grade of recommendation
1.1. Once a diagnosis of APL is suspected, the disease should be managed as a medical emergency. IV C
1.2. Diagnosis should be confirmed by molecular detection of PML-RARA fusion (or rare molecular variants). IIa B
1.3. In addition to conventional karyotyping, FISH, and RT-PCR, immunostaining with anti-PML antibody can
be used for rapid diagnosis of APL.
IIa B
Management of coagulopathy
1.4. Treatment with ATRA should be started immediately that a diagnosis of APL is suspected. Ib A
1.5. Liberally transfuse with fresh frozen plasma, fibrinogen, and/or cryoprecipitate and platelet
transfusions to maintain the fibrinogen concentration and platelet count above 100-150 mg/dL and
30-50  109/L, respectively.
IIb B
1.6. The benefit of heparin, tranexamic acid, or other anticoagulant or antifibrinolytic therapy remains
questionable and should not be used routinely outside the context of clinical trials.
IV C
Management of hyperleukocytosis (WBC >10  109/L)
1.7. Chemotherapy should be started without delay, even if the molecular results are still pending. IV C
1.8. Leukopheresis should be avoided due to risk of precipitating fatal hemorrhage. III B
1.9. Prophylactic steroids can be given, which may reduce the risk of APL differentiation syndrome. IV C
Management of APL differentiation syndrome
1.10. Steroids (10 mg dexamethasone intravenously bd) should be started immediately at the earliest
clinical suspicion of incipient APL differentiation syndrome. Once the syndrome has resolved, steroids
can be discontinued and ATO/ATRA recommenced.
IIa B
1.11. Temporary discontinuation of differentiation therapy (ATRA or ATO) is indicated only in case of
severe APL differentiation syndrome.
IIa B
Management of treatment with ATO
1.12. Treatment with ATO should be restricted to cases confirmed to be PML/RARA-positive. IIb B
1.13. Treatment with ATO requires careful monitoring to maintain electrolytes in the normal range, keeping
the serum potassium above 4.0 mEq/L and serum magnesium above 1.8 mg/dL.
IV C
1.14. Treatment with ATO requires careful monitoring of the QT/QTc interval.* IV C
*If the QT (or QTc for patients with heart rate 60 beats per minute) interval is prolonged longer than 500 msec, ATO should be withheld, the electrolytes (potassium and
magnesium) repleted, and other medications that may cause prolonged QTc interval searched for and, ideally, discontinued. Once the QT/QTc returns to approximately
460 msec and the electrolytes are repleted, ATO may be resumed.
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banking (recommended), confirmation of diagnosis at the genetic
level, and monitoring MRD by RT-PCR, should receive samples as
follows:
FISH or immunostaining For FISH or immunostaining studies,
3 to 4 BM smears and 3 to 4 PB smears at diagnosis are required.
Samples can be sent at ambient temperature. Smears that are not
used immediately must be stored for banking at20°C, covered by
aluminum paper.
PML-RARA analysis. For RNA extraction and RT-PCR
analysis of PML-RARA, one BM aspirate vial (2-3 mL) and one PB
vial (20-30 mL), both in sodium citrate or ethylenediaminetetraace-
tic acid (EDTA), are required. Samples should be processed within
24 hours. Isolated mononuclear cells in guanidium isothiocyanate
can be stored for banking at20°C.
Karyotyping and FISH. For conventional karyotyping and
FISH studies, BM aspirate (1-2 mL) should be collected in heparin
and dispatched at ambient temperature. Samples will be processed
on arrival for these diagnostic studies and pelleted nuclei fixed with
methanol and acetic acid (3:1) can be stored at20°C.
Other genetic studies. Mutations in the gene encoding the
fms-like tyrosine kinase 3 (FLT3) are seen more frequently in APL
than in other subtypes of AML.42 However, although FLT3
mutations are associated with a higher white blood cell (WBC)
count at presentation, they do not add to the specific diagnosis of
APL or influence management, nor do they furnish important
independent prognostic information.43,44 Therefore, the inclusion of
the analysis of these mutations in the routine work up of APL is not
recommended on the basis of current evidence. Although APL has a
characteristic gene expression signature on microarray45,46 and this
may provide a useful additional diagnostic tool in the future, for the
time being this approach remains in the research arena.
3.2. Institution of supportive measures to counteract the
coagulopathy
Intracerebral and pulmonary hemorrhages are relatively common
life-threatening complications occurring while the characteristic
coagulopathy of APL is active. These complications are not only
the most frequent cause of death early during induction therapy but
can also occur before the diagnosis of APL has been made and
therapy started. Data about the proportion of patients developing
such hemorrhages before starting induction therapy are extremely
scarce in the literature. In general, major series have not provided
details about patients considered not eligible for treatment because
of poor clinical condition. The US Intergroup47 and the Programa
de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA)
group48 have reported around 5% of patients considered not
eligible for induction therapy due to very poor clinical condition
(Eastern Cooperative Oncology Group [ECOG] performance status
3), mostly due to lethal or life-threatening hemorrhages before
starting therapy.49 In this context, it is reasonable to recommend
that supportive measures to counteract the coagulopathy should be
instituted immediately the diagnosis of APL is considered and
consist of fresh frozen plasma, fibrinogen and/or cryoprecipitate
and platelet transfusions to maintain the fibrinogen concentration
and platelet count above 100 to 150 mg/dL and 30 to 50 109/L,
respectively, which should be monitored at least once a day (more
frequently if required). Such replacement therapy should continue
during induction therapy until disappearance of all clinical and
laboratory signs of coagulopathy. Despite a need-adapted transfu-
sion policy under strict monitoring of the coagulopathy, patients
presenting some factors have a higher risk of developing a fatal
hemorrhage. These factors are the following: patients with active
bleeding,50 hypofibrinogenemia (100 mg/dL),51 or increased lev-
els of fibrin degradation products or D-dimers combined with
prolonged prothrombin time or activated partial thromboplastin
time,48 as well as those presenting with increased WBC52,53 or
peripheral blast48,50 counts, abnormal levels of creatinine,48 or poor
performance status.51 Further investigation is warranted in these
patients.
Central venous catheterization, lumbar puncture, and other
invasive procedures (eg, bronchoscopy) should be avoided before
and during remission induction therapy due to high risk of
hemorrhagic complications. In addition, it has been also suggested
that an exacerbation of the distinctive procoagulant state of APL
may lead not only to increase the hemorrhagic risk but also to a
higher incidence of thrombosis. The benefit of heparin, tranexamic
acid, or other anticoagulant or antifibrinolytic therapy to attenuate
the hemorrhagic risk remains questionable and these agents should
not be used routinely outside the context of clinical trials. There are
also case reports of the use of recombinant factor VIIa in the
situation of severe life-threatening hemorrhage.54,55
3.3. Initiation of treatment with ATRA
Treatment with ATRA should be initiated without waiting for
genetic confirmation of the diagnosis, preferably the same day that
diagnosis is suspected. Although there is no evidence supporting
this recommendation, it is reasonable to presume a favorable
risk-benefit ratio associated with this approach; moreover, ATRA is
unlikely to have any deleterious effect should genetic assessment
fail to confirm the diagnosis of APL. ATRA is known to improve
the biologic signs of APL coagulopathy rapidly; hence early
initiation of this agent is likely to decrease the risk of severe
bleeding. The supportive measures to be adopted upon institution
of ATRA therapy are discussed below. Since APL treatment
protocols are now specific for cases with documented PML-RARA
fusion, for those presenting with low WBC count, administration of
appropriate chemotherapy may be delayed until the genetic diagnosis is
confirmed; however, in patients with hyperleukocytosis (eg,
WBC 10 109/L), due to the high risk of induction death and
retinoic acid syndrome, chemotherapy should be started without delay
even if the molecular results are still pending (see section 5.1.2).
4. Appropriate setting for the management of
APL
The recommendations by the British Committee for Standards in
Hematology (BCSH) in the recently published Guidelines on the
management of acute myeloid leukemia in adults15 can be gener-
ally assumed for the management of APL. However, the peculiari-
ties of APL deserve some additional comments and specific
recommendations. In brief, the BCSH recommends that patients
with AML should be managed by a multidisciplinary team serving
a population of no fewer than 500 000 and that acute leukemia
induction therapy should only be carried out in those centers
treating at least 5 patients per year with intensive chemotherapy.
According to this recommendation, centers treating 5 to 10 AML
patients per year would have the opportunity of treating no more
than one APL patient every 2 years. Although this limits experience
of APL management at smaller centers, it is clear that optimum
clinical treatment is dependent upon rapid access to diagnosis and
hospital facilities with ATRA and blood products. This highlights
the importance of guidelines to raise clinical awareness of the rapid
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actions needed for diagnosis and rigorous supportive care aspects
to reduce the risk of induction death irrespective of the size of the
treatment center.
5. Treatment of newly diagnosed patients
5.1. Supportive care
Recommendations for supportive care measures are summarized in
Table 1.
5.1.1. Specific supportive measures. Besides the specific
supportive measures intended to reduce morbidity and mortality
associated with the characteristic coagulopathy that were described
above (section 3.2), other measures should be instituted to reduce
some clinical complications typically associated with the adminis-
tration of ATRA and ATO, such as the APL differentiation
syndrome (formerly retinoic acid syndrome) seen with both agents,
and several electrolyte abnormalities and prolongation of the QT
interval which can occur with ATO therapy.
5.1.1.1. Prevention and management of APL differentiation
syndrome. Physicians caring for patients with APL treated with
ATRA or ATO should be aware of early symptoms or signs
suggestive of the APL differentiation syndrome. Diagnosis of this
syndrome should be suspected clinically in the presence of one of
the following symptoms and signs: dyspnea, unexplained fever,
weight gain, peripheral edema, unexplained hypotension, acute
renal failure or congestive heart failure, and particularly by a chest
radiograph demonstrating interstitial pulmonary infiltrates, or pleu-
ropericardial effusion. Because of the life-threatening nature of the
full-blown syndrome, specific treatment with dexamethasone at a
dose of 10 mg twice daily by intravenous injection should be
started promptly at the very earliest symptom or sign. This policy is
highly recommended even though none of the aforementioned
signs and symptoms is pathognomonic of the syndrome, and they
can be due to concurrent medical problems, such as bacteremia,
sepsis, fungal infection or congestive heart failure. Temporary
discontinuation of ATRA or ATO is indicated only in case of severe
APL differentiation syndrome (ie, patients developing renal failure
or requiring admission to the intensive care unit due to respiratory
distress). Otherwise, these differentiating agents could be main-
tained unless progression to overt syndrome or lack of response to
dexamethasone is observed. If a favorable response is obtained,
dexamethasone should be maintained until complete disappearance
of symptoms, and then ATRA or ATO should be resumed. While
preemptive therapy with dexamethasone currently represents the
standard approach to treat patients developing APL differentiation
syndrome, there is at present no evidence that prophylactic
corticosteroid is advantageous to reduce rates of morbidity and
mortality associated with this syndrome. Nevertheless, in uncon-
trolled studies, a very low mortality or morbidity rate was reported
as a result of differentiation syndrome after ATRA treatment when
corticosteroids were administered prophylactically in patients
presenting with WBC count greater than 5 109/L.56,57
5.1.1.2. Prolonged QT interval associated with ATO. Treat-
ment with ATO is associated with several electrolyte abnormalities
and QT prolongation that can lead to a torsade de pointes-type
ventricular arrhythmia, which can be fatal.58 This requires careful
monitoring to maintain the serum potassium above 4.0 mEq/L and
serum magnesium above 1.8 mg/dL, well above the lower limit of
normal. If possible, drugs that are known to prolong the QT interval
should be discontinued. In patients who reach an absolute QT
interval value longer than 500 msec, ATO should be withheld, the
electrolytes (potassium and magnesium) repleted, and other medi-
cations that may cause prolonged QT interval searched for and
ideally discontinued. The risk/benefit of continuing versus suspend-
ing arsenic therapy should be considered in any case. If syncope,
rapid or irregular heartbeat develops, the patient should be hospital-
ized for ECG and electrolyte monitoring and ATO therapy should
be temporarily discontinued. Once the QT/QTc returns to approxi-
mately 460 msec, the electrolytes are repleted, and the syncope and
irregular heartbeat cease, ATO may be resumed. In addition to
prolongation of the QT/QTc interval, approximately 13% of
patients treated with ATO may develop hypokalemia or
hyperglycemia.
5.1.2. Other supportive measures. Apart from the aforemen-
tioned specific measures, general supportive care aspects in APL,
the use of antibiotics, hematopoietic growth factors, prevention of
tumor lysis syndrome, and transfusion policy, including red cell,
granulocyte, and platelet transfusions (once the coagulopathy is
under control), do not differ from those applied in patients with
other subtypes of AML.15
However, leukapheresis is not recommended as part of initial
therapy for APL patients presenting with elevated WBC, because
this procedure may exacerbate the coagulopathy and was associ-
ated with a high risk of induction death in one series.59 Early
institution of chemotherapy in combination with ATRA accompa-
nied by prophylactic steroids is the standard treatment approach in
this life-threatening situation. In patients presenting with WBC
count greater than 10 109/L, chemotherapy is generally started
on day 1 within a few hours of the first dose of ATRA, aiming to
control the coagulopathy while reducing the risk of APL differentia-
tion syndrome which is particularly high in these patients. On the
other hand, treatment-related hyperleukocytosis, which frequently
develops during induction with ATO, can be safely managed with
careful observation, checking in particular for evidence of emerg-
ing APL differentiation syndrome (see section 5.1.1.1, “Prevention
and management of APL differentiation syndrome”).60 Approxi-
mately 50% of patients treated with ATO develop leukocytosis,
with a peak WBC count at approximately 20 days after the first
dose. In the situation of marked hyperleukocytosis after ATO,
administration of hydroxyurea can be considered although its
clinical benefit is unclear; however, such leukocytosis resolves at a
median of 10.5 days after the peak, despite continuation of ATO.
5.2. Targeted treatment
Recommendations for management during and after induction and
consolidation therapy are summarized in Table 2.
5.2.1. Induction therapy.
5.2.1.1. The current standard approach. The simultaneous
administration of ATRA and anthracycline-based chemotherapy is
currently considered the standard induction treatment in newly
diagnosed patients with APL. This combination results in ex-
tremely high antileukemic efficacy, leading to complete remission
(CR) in 90% to 95% of patients and primary resistance has been
only reported in just a few anecdotal cases.50,52,53,57 These data
indicate that virtually all PML-RARA–positive APLs are sensitive
to ATRA and anthracycline-based chemotherapy. Several other
clinical trials conducted over the last decade have led to the
optimization of ATRA and anthracycline-containing chemotherapy
schedules.9,10,12,13 Initial studies involving ATRA monotherapy,
which also resulted in high rates of CR, highlighted the need for
administering some type of consolidation chemotherapy to avoid
disease relapse. Several subsequent studies and especially 2 random-
ized trials of the European APL group61 and the North American
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Intergroup,47 showed that patients receiving ATRA followed by
chemotherapy had significantly better outcomes compared with
patients treated with chemotherapy alone. In both studies, the CR
and early death rates were not statistically different, but the relapse
rate was significantly higher for the patients treated with chemo-
therapy alone. The outcomes with the sequential administration of
ATRA followed by chemotherapy were subsequently improved on
over the past decade when ATRA and chemotherapy were given
simultaneously. This was clearly shown in a randomized study of
the European APL group52 comparing the sequential versus the
simultaneous ATRA plus chemotherapy schedule, and further
confirmed in other large multicenter trials.53,57,62-65 Based on these
studies, an evidence-based consensus has been reached to establish
the combination of ATRA plus anthracycline-based chemotherapy
as the current standard approach for newly diagnosed APL.
As to the type of anthracycline and whether it should be
combined with other chemotherapy agents, both issues still remain
controversial; at least as far as induction therapy is concerned.
Comparable CR rates have been reported using ATRA plus
daunorubicin and cytarabine52,66 andATRAplus idarubicin alone,62,64
with no apparent advantage observed by adding other cytotoxic
agents.53 The only randomized trial reported so far67 was unable to
demonstrate differences in terms of CR and induction failure rates
when comparing ATRA plus daunorubicin alone versus ATRA plus
daunorubicin plus cytarabine for induction therapy. However, this
study demonstrated an increased risk of relapse when cytarabine
was omitted from both induction and consolidation therapy. A
preliminary result of a second randomized trial has recently been
reported which compared ATRA with idarubicin against ATRA
with daunorubicin and cytarabine. There was no overall difference
in response, relapse, or overall survival, but a small increase in
deaths in remission was noted in the cytarabine-containing arm.68
With respect to the type of anthracycline, idarubicin has shown a
slight survival advantage compared with daunorubicin in conjunc-
tion with cytarabine only in younger AML patients.69 In APL, no
prospective studies have been conducted to assess the comparative
value of both anthracyclines.
Exceptions to the use of the standard approach should be
considered only for individual cases in which chemotherapy is
contraindicated (eg, severe organ failure, anticoagulant therapy,
patients older than 80 years), as well as in cases in which
alternative options for induction therapy are dictated by socioeco-
nomic factors or clinical trial design. However, modifications to the
standard approach based on the presence of leukemia-cell character-
istics that have variably been considered to predict a poorer
Table 2. Management during induction, consolidation therapy, and beyond
Recommendation Level of evidence Grade of recommendation
2.1. Eligible patients should be offered entry into a clinical trial. IV C
Induction therapy
2.2. Induction therapy should consist of the administration of concomitant ATRA and anthracycline-based
chemotherapy.
Ib A
2.3. Standard induction therapy should not be modified based on the presence of leukemia cell characteristics
that have variably been considered to predict a poorer prognosis (eg, secondary chromosomal abnormalities,
FLT3 mutations, CD56 expression, and BCR3 PML-RARA isoform).
IIa B
2.4. ATO should be used as standard therapy in countries where pharmaceutical quality locally produced
arsenic compounds provide a more affordable treatment approach than ATRA plus chemotherapy.
III B
2.5. Treatment with ATRA should be continued until terminal differentiation of blasts and achievement of CR,
which occurs in virtually all patients after conventional ATRA  anthracycline induction schedules.
IIa B
2.6. Clinicians should refrain from making therapeutic modifications on the basis of incomplete blast maturation
(differentiation) detected up to 50 days or more after the start of treatment by morphology, cytogenetics, or
molecular assessment.
IV C
Consolidation therapy
2.7. Two or 3 courses of anthracycline-based chemotherapy are considered the standard approach for
consolidation therapy.
Ib A
2.8. The addition of ATRA to chemotherapy in consolidation seems to provide a clinical benefit. IIb B
2.9. Consolidation for high-risk patients younger than 60 years with WBC counts higher than 10  109/L
should include at least one cycle of intermediate- or high-dose cytarabine.
IIb B
2.10. ATO in consolidation should at present be restricted to investigation within clinical trials or those patients
considered unfit for conventional chemotherapy.
IV C
2.11. Molecular remission in the bone marrow should be assessed at completion of consolidation by RT-PCR
assay affording a sensitivity of at least 1 in 104.
IIa B
2.12. Patients with confirmed molecular persistence should be considered for allogeneic HSCT. IV C
2.13. For patients with molecular persistence who are not candidates for allogeneic HSCT, ATO or
gemtuzumab ozogamicin may be considered.
IIa B
Management after consolidation
2.14. Maintenance therapy should be used for patients who have received an induction and consolidation
treatment regimen wherein maintenance has shown a clinical benefit.
Ib A
2.15. Because early treatment intervention in patients with evidence of MRD affords a better outcome than
treatment in full-blown relapse, every 3 months MRD monitoring of bone marrow should be offered to all
patients for up to 3 years after completion of consolidation therapy.
IIb B
2.16. Bone marrow generally affords greater sensitivity for detection of MRD than blood and therefore is the
sample type of choice for MRD monitoring to guide therapy.
IIa B
2.17. For patients testing PCR-positive at any stage after completion of consolidation, it is recommended that a
bone marrow is repeated for MRD assessment within 2 weeks and that samples are sent to the local
laboratory, as well as to a reference laboratory for independent confirmation.
IV C
2.18. CNS prophylaxis can be considered only for patients with hyperleukocytosis. IV C
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prognosis (eg, secondary chromosomal abnormalities, FLT3 muta-
tions, CD56, and BCR3 or short PML-RARA isoform) are not
supported by the available data.
5.2.1.2. ATO as an alternative approach. After the successful
results in the treatment of relapsed patients with APL first reported
in China and then replicated in Western populations,70,71 several
trials have been designed to investigate the role of ATO in front-line
therapy. As far as we know, only 4 relatively small and selected
series using ATO from China,72 Iran,73 India,74 and M.D. Anderson
Cancer Center (Houston, TX)75 have been published so far. The CR
rate in these studies ranged from 86% to 95%. However, it should
be noted that ATO was combined with ATRA72,75 and/or chemo-
therapy72,74 and/or gemtuzumab ozogamicin75 in a variable propor-
tion of patients, particularly those presenting with hyperleukocytosis.
Altogether, these promising results with ATO-based regimens
indicate that appropriately designed comparisons with the standard
ATRA plus anthracycline chemotherapy approach in terms of
efficacy, safety, and cost-effectiveness are warranted. In the
meantime, the use of ATO-based regimens should be restricted to
patients included in clinical trials or for those in whom chemo-
therapy (especially anthracyclines) is contraindicated. Neverthe-
less, it should be remarked that, in countries where locally
produced arsenic compounds provide a more affordable treatment
approach than ATRA plus chemotherapy, arsenic-based regimens
have been adopted as the standard of care. In this scenario, a
cheaper ATO, produced under good quality control, would be
effective in curing many APL patients.
5.2.1.3. Assessment of induction response. Results of morpho-
logic, cytogenetic, and molecular evaluation should be cautiously
interpreted at the end of induction therapy. Morphologic features in
BM during differentiation therapy can lead to erroneously labeling
some patients as resistant by inexperienced pathologists. In fact,
potentially misleading cytomorphologic features due to incomplete
blast maturation are occasionally seen even after several weeks
from treatment initiation (up to 40-50 days). Similarly, a delayed
differentiation of blasts can lead to the detection of cells displaying
the t(15;17) by conventional cytogenetics or FISH, particularly
when these tests are performed at an early time after induction.
These morphologic and cytogenetic assessments should not lead to
any treatment modification. Rather, treatment with ATRA should be
continued allowing sufficient time for terminal differentiation of
blasts to occur. As discussed above, CR is attained in virtually all
patients with genetically proven PML-RARA APL. In this respect, a
recent study by the PETHEMA group48 found that 6 of the
7 patients who were registered by their physicians as having
primary resistant disease among 739 patients treated with ATRA
plus idarubicin had been assessed for response much earlier than is
currently recommended (ie, while still pancytopenic, 18-33 days
after chemotherapy).8,41 Unfortunately, the premature administra-
tion of salvage therapy to these patients precluded the possibility to
determine whether they genuinely exhibited primary resistance or
whether in these instances there was merely a delay in terminal
differentiation of APL blasts. In case of any doubt about the
achievement of CR, it is recommended to repeat another BM
assessment after an additional interval of 2 to 3 weeks while
keeping the patient on ATRA, and meanwhile to refrain from new
therapeutic interventions. Since the introduction of this strategy, no
cases of resistant leukemia have been recorded among the last
350 patients enrolled in the PETHEMA studies.48
Molecular assessment by RT-PCR on regeneration after induc-
tion has no clinical relevance, because PCR positivity at this early
time point may simply reflect delayed maturation instead of
resistance. Therefore, clinicians should refrain from making thera-
peutic decisions on the basis of results at this time point. In sharp
contrast, results of PCR analyses performed after completion of
consolidation are relevant to determine the relapse risk in the
individual patient (see section 5.2.2.6).
5.2.2. Consolidation therapy. The achievement of molecular
remission rates of roughly 95% in patients receiving at least
2 further cycles of anthracycline-based chemotherapy after induc-
tion has led to the adoption of this strategy as the standard for
consolidation.8 However, some issues related to this phase of
therapy remain controversial and will be discussed in detail.
5.2.2.1. The role of all-trans retinoic acid. The benefit pro-
vided by the addition of ATRA to chemotherapy for consolidation
has not yet been demonstrated in randomized studies. Nevertheless,
historical comparisons of consecutive trials carried out indepen-
dently by the Gruppo Italiano Malattie Ematologiche dell’Adulto
(GIMEMA)76 and PETHEMA57 groups showed a statistically
significant improvement in outcomes when ATRA at standard dose
(45 mg/m2 per day for adults; 25 mg/m2 per day for children) was
given for 15 days in conjunction with chemotherapy, suggesting
that ATRA contributes to reduction in relapse risk.
5.2.2.2. The role of cytarabine. From the first successful
regimen using daunorubicin as monotherapy77 to the present, the
role of cytarabine in APL has remained controversial. None of the
studies conducted in the pre-ATRA era, including a randomized
one,78 showed an advantage for addition of cytarabine to anthracy-
clines compared with using high-dose anthracyclines as single
agents. With the incorporation of ATRA into most state-of-the-art
regimens, the controversy about the role of cytarabine has re-
mained unresolved. A recent randomized study by the European
APL group67 reported an increased risk of relapse when cytarabine
was omitted from a schedule including daunorubicin. The conclu-
sions of this interesting study, however, should be interpreted with
caution. As a matter of fact, the results of this study might have
been largely dependent on the particular choice and dose of
anthracycline chemotherapy used (daunorubicin at a cumulative
dose of 495 mg/m2). Of note, a joint analysis of the PETHEMA and
the European APL groups79 demonstrated a significantly lower
cumulative incidence of relapse in patients younger than 65 years
with WBC counts less than 10 109/L at presentation who were
treated with anthracycline monochemotherapy (ie, with no cytara-
bine) in the PETHEMA LPA99 trial compared with patients in the
best arm of the European APL 2000 trial including cytarabine.
However, a trend in favor of cytarabine administration was
observed in the same joint study for high-risk patients with WBC
counts higher than 10 109/L. A possible explanation for these
discrepancies between chemotherapy regimens with or without
cytarabine could be the different type and/or dosing schedule of the
anthracyclines involved. Whereas the PETHEMA protocol used
idarubicin (cumulative dose, 80-100 mg/m2) and mitoxantrone
(cumulative dose, 50 mg/m2), the European APL protocol used
daunorubicin (cumulative dose, 495 mg/m2). Indeed, a previous
joint analysis of the PETHEMA and GIMEMA group studies that
used identical type and dosage schedules of anthracyclines showed
no difference in outcome with the addition of other chemotherapy
agents, including cytarabine, in the GIMEMA group study.80
Similarly, the preliminary results of the MRC15 trial which were
referred to earlier, did not show a benefit for the cytarabine
containing arm irrespective of the white blood count.60 However, in
keeping with results of the joint analysis of the PETHEMA and
European APL groups,79 the most recent Italian study does suggest
a benefit for using cytarabine in combination with ATRA in
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consolidation in patients with high-risk disease (ie, presenting
WBC 10  109/L).76 Therefore, in summary, the majority of
studies suggest a potential benefit in terms of reduction of relapse
risk for the addition of at least one cycle of intermediate or
high-dose cytarabine in patients younger than 60 years with WBC
counts higher than 10 109/L but no difference in overall survival.
5.2.2.3. The role of ATO. The role of ATO in postinduction
therapy for newly diagnosed APL patients has been explored not
only to consolidate CR aiming to minimize or even eliminate
chemotherapy,72-75 but also to reinforce standard ATRA plus
chemotherapy regimens. Results of the 4 studies using ATO for
induction and postremission therapy showed a high antileukemic
activity of this agent. However, as discussed above, the use ATO in
front-line therapy should at present be restricted to investigation
within clinical trials or the treatment of those patients considered
unfit for conventional chemotherapy. Recently, the use of ATO to
reinforce standard ATRA plus chemotherapy regimens has been
supported by a large randomized study by the US Intergroup.66 In
this study, patients receiving 2 courses of 25 days of ATO (5 days a
week for 5 weeks) immediately after the patient entered a CR and
before the standard postremission regimen with 2 more courses of
ATRA plus daunorubicin had a significantly better event-free and
overall survival than those who received only ATRA plus chemo-
therapy. This interesting study, although providing high-level
evidence for the use of ATO in consolidation, does not definitively
clarify whether reinforcement of consolidation therapy with this
agent improves the outcome of a given “standard therapy,” because
overall survival in the control arm was relatively low compared
with rates reported by other groups using ATRA and anthracycline
chemotherapy–based schedules. The results in the pediatric age
group in the US Intergroup study were particularly disappointing
compared with other standard approaches.81-84 Future studies will
address whether ATO can allow deintensification of APL therapy
without compromising cure rates or indeed improve on outcomes
currently achieved with optimal ATRA and anthracycline–based
protocols.
5.2.2.4. The role of hematopoietic stem cell transplantation.
The role of hematopoietic stem cell transplantation (HSCT) in
front-line therapy of APL has changed dramatically during recent
years. In fact, the high cure rate obtained using upfront ATRA and
chemotherapy indicates that there is no role for routine use of
HSCT for patients who are in the first molecular remission at the
end of consolidation. For the small fraction of patients with
persistent MRD at this time point, given the poor prognosis of this
subset of patients,85 allogeneic HSCT should be considered for
those with a suitable human leukocyte antigen (HLA)–matched
donor available. Because this group can progress rapidly to overt
relapse, additional therapy (eg, ATO) can be used to reduce disease
burden and ideally achieve molecular CR before transplantation.
For the time being, nearly all experience in HSCT has been based
on the use of ablative conditioning regimens. Data after reduced-
intensity conditioning in this disease are currently lacking. For
those who are not candidates for allogeneic HSCT because a
suitable HLA-matched donor is not available or the overall
performance and clinical condition render the patient unsuitable for
transplantation, other experimental options such as ATO, gemtu-
zumab ozogamicin, or both should be considered. Provided that the
patient achieves molecular CR in the marrow and has a PCR
negative harvest autologous HSCT can be considered as consolida-
tion therapy. Although good results have been achieved using this
approach,86,87 the role of transplant is uncertain, since it is possible
that long-term remissions can also be achieved with multiple
courses of ATO and/or gemtuzumab ozogamicin.
5.2.2.5. Risk-adapted consolidation. It is generally assumed
that older patients are more vulnerable to chemotherapy toxicity
and most protocols limit the age to receive full-dose chemotherapy
not only for consolidation, but also for induction. Even with
therapeutic approaches that have been demonstrated to have a
relatively low toxicity, such as the PETHEMA treatment schedules,
mortality rate in CR ranged from less than 1% in patients younger
than 60 to 19% in patients older than 70 years.88 Therefore, it is a
reasonable option to design therapeutic strategies to reduce treatment-
related morbidity and mortality in this setting. In addition, there is a
tendency to design risk adapted strategies to modulate treatment
intensity in consolidation according to predefined risk factors for
relapse, particularly presenting WBC.80 This tailored strategy seems to
be an efficient approach to minimize toxicity while targeting more
intensive therapy to those patients at most risk of relapse.
5.2.2.6. Molecular assessment at the end of consolidation and
beyond. In contrast to the lack of clinical value of molecular
assessment performed at the end of induction (see section 5.2.1.3),
RT-PCR of PML-RARA in BM carried out on regeneration after the
final course of chemotherapy is extremely relevant to determine the
relapse risk in the individual patient.23,89 The achievement of
molecular remission at this time point represents a therapeutic
milestone and is considered a major treatment objective as
recommended by the International Working Group for the standard-
ization of response criteria in AML.41 The evidence supporting this
statement was obtained using conventional nested RT-PCR assays,
which afford a relatively low sensitivity, typically detecting
1 leukemic cell in 103 to 104 cells in BM. Real-time quantitative
PCR (RQ-PCR) assays are marginally more sensitive and provide
several advantages.90 In particular, they are less prone to contami-
nation, allow kinetics of disease response and relapse to be defined,
and enable poor quality samples that could have given rise to “false
negative” results according to conventional RT-PCR assays to be
identified based upon the level of endogenous control gene
transcripts (eg, ABL).89 For patients testing PCR-positive at any
stage after completion of consolidation, it is recommended that a
BM is repeated for MRD assessment within 2 weeks and that
samples are sent to the local laboratory, as well as to a reference
laboratory for independent confirmation. It is now accepted that
patients with persistent or recurrent disease at the molecular level
confirmed in 2 consecutive low-sensitivity assays after completion
of consolidation will invariably relapse unless additional therapy is
given.85,91 The optimal management for patients with documented
molecular relapse is uncertain and has been already discussed in
section 5.2.2.4, “The role of hematopoietic stem cell
transplantation.”
5.2.3. Maintenance therapy. Despite the benefit provided by
ATRA-based maintenance therapy in 2 randomized studies,47,52 the
systematic use of postconsolidation therapy is still a controversial
matter in patients achieving molecular remission at the end of
consolidation. As the molecular status at the end of consolidation
had not been tested in these studies, it might be possible that a
proportion of patients with levels of residual disease within the
PCR-detectable range benefited from maintenance. Two other
randomized studies, however, have recently reported no benefit
from 2 different maintenance regimens.92,93 It should be noted,
however, that these studies were carried out in patients testing
negative for PML/RARA at the end of consolidation. The Italian
study involving ATRA, 6-mercaptopurine, and methotrexate has
been published only in abstract form to date92 and the Japanese
study,93 using 6 courses of intensified maintenance chemotherapy
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without ATRA, showed no benefit in terms of reducing relapse rate
and moreover was associated with a significantly poorer chance of
survival. These conflicting data indicate that the relative benefit of
maintenance depends upon the prior induction and consolidation
therapy. Therefore, it is appropriate to use maintenance in conjunc-
tion with protocols in which it has been shown to confer benefit.
Despite the uncertainty of the benefit provided by maintenance
therapy, it is a fact that several patients PCR-negative at the end of
consolidation will ultimately relapse, especially among those
presenting with WBC count higher than 10 109/L. Previous
studies have shown that the majority of these patients can be
identified by sequential MRD monitoring using qualitative or
quantitative PCR, allowing the opportunity for preemptive therapy
to prevent disease progression to overt morphologic relapse.90,94,95
5.3. Central nervous system prophylaxis
The central nervous system (CNS) is the commonest site of
extramedullary disease in APL and at least 10% of hematologic
relapses are accompanied by CNS involvement.96 Therefore, the
possibility of CNS disease should be considered in any APL patient
with neurologic symptoms and be excluded in patients subject to
relapse.
It was suggested, early in the ATRA era, that there was a
possible association between development of extramedullary dis-
ease and the use of ATRA. However, a large study of the
GIMEMA, carried out in patients treated with or without ATRA,
failed to demonstrate this correlation.97 Rather, it is conceivable
that extramedullary relapses are more apparent, given the greater
availability of molecularly targeted therapies and prolonged sur-
vival of patients. Because the majority of CNS relapses occur in
patients presenting with hyperleukocytosis,98 some strategies in-
clude CNS prophylaxis for patients in this particular high-risk
setting. For such patients, it is advisable to postpone CNS
prophylaxis until after the achievement of CR because lumbar
puncture at presentation and during induction is extremely hazard-
ous. However, the benefit of this policy has not been established.
For patients without hyperleukocytosis, in whom the risk of CNS
relapse is extremely low, there is a general consensus to avoid CNS
prophylaxis.
6. Management of special situations
Recommendations for the management of special situations are
summarized in Table 3.
6.1. Older patients
Unlike other forms of AML arising in older patients, APL is
relatively uncommon in this age group and has a relatively
favorable outcome. In fact, older patients with APL seem at least as
responsive to therapy as do younger patients. In addition, older
patients are more likely to present with low-risk features compared
with younger patients.88 To some extent, this observation may
explain the relatively low relapse rate observed in patients more
than 70 years of age receiving ATRA and moderately reduced
anthracycline-based chemotherapy.88,99 However, as mentioned in
section 5.2.2.5 (“Risk-adapted consolidation”), it is generally
assumed that older patients are more vulnerable to therapy-related
Table 3. Management of special situations
Recommendation Level of evidence Grade of recommendation
Older patients
3.1. Elderly patients in good clinical condition should be managed with a treatment approach similar to that
used in younger patients slightly attenuated in dose intensity.
IIa B
Patients with severe comorbidities
3.2. Older and younger patients with severe comorbidities unfit for chemotherapy (especially
anthracyclines) are candidates to receive ATO-based treatment schedules.
III B
Children
3.3. ATRA at 25 mg/m2 per day is the recommended dose in children and adolescents. IIa B
Pregnant women
3.4. Management of APL in pregnancy requires the involvement of the patient, hematologist, obstetrician,
and neonatologist.
III B
3.5. Retinoids are highly teratogenic and should be avoided in the first trimester unless the patient decides
to have a termination of pregnancy.
III B
3.6. ATRA can be used in the second and third trimesters of pregnancy. III B
3.7. Arsenic derivatives are highly embryotoxic and are contraindicated at any stage of pregnancy. IV C
3.8. In patients presenting in the first trimester and not wishing to have a termination of pregnancy,
induction therapy with daunorubicin alone can be offered.
IV C
3.9. Although chemotherapy appears reasonably safe in the second and third trimesters of pregnancy, it is
associated with an increased risk of abortions and premature delivery, and induction of labor between
cycles of chemotherapy should be considered.
III B
3.10. Stringent fetal monitoring, with particular emphasis on cardiac function, is recommended for patients
receiving ATRA with or without chemotherapy during pregnancy.
IV C
3.11. For deliveries before 36 weeks of gestation, antenatal corticosteroids before preterm delivery are
recommended to reduce the risk of morbidity and mortality associated with respiratory distress
syndrome.
IIb B
3.12. After successful delivery, breastfeeding is contraindicated if chemotherapy or ATO is needed. IV C
3.13. Female patients with APL should be advised against conceiving while exposed to ATRA or ATO for
consolidation and maintenance therapy.
IV C
Management of therapy-related APL
3.14. Patients with tAPL should the treated like those with de novo APL, but modifications may be
necessary taking into account cardiac toxicity and prior anthracycline exposure.
III B
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toxicity (higher rates of neutropenic sepsis and increased treatment-
related mortality). Even with therapeutic approaches that have
demonstrated a relatively low toxicity, such as the PETHEMA
protocols, mortality rate in CR ranged from less than 1% in patients
younger than 60 to 19% in patients older than 70 years.88 Therefore,
it is reasonable to design therapeutic strategies aiming to reduce
morbidity and mortality due to chemotherapy in this setting and
very especially for those unfit for more intensive therapy. For the
frail patients who are considered unfit for conventional treatment,
ATO with or without ATRA might be a reasonable alternative to the
standard ATRA plus chemotherapy approach, although supporting
scientific data currently are limited, particularly with respect to
rates of remission and complications such as APL differentiation
syndrome.75
6.2. Patients with severe comorbidities
Several alternative front-line treatment approaches have been
designed to minimize the use of chemotherapy in APL. Most of
these are based on the use of ATRA, ATO, and gemtuzumab
ozogamicin, with minimal or no chemotherapy75 (see section 5.2.1,
“Induction therapy”). Although information on long-term outcome
using these alternative approaches in unfit patients is lacking, they
could reasonably be used for older and younger patients with
severe comorbidities in which intensive chemotherapy is contrain-
dicated (eg, patients with cardiac impairment or other severe organ
dysfunction). As with conventional ATRA and anthracycline–based
chemotherapy, the aim of treatment in such patients should be to
achieve molecular remission, with MRD monitoring being used to
guide the need for additional therapy.
6.3. Children
APL accounts for 4% to 8% of pediatric AML in the United
States.100 Higher proportions of APL in pediatric series have been
reported from other areas of the world, especially from Italy and
Central and South America,101-103 but most of these studies share
many methodologic limitations and deserve additional investiga-
tion. Compared with the disease in adults, APL diagnosed in
childhood more frequently presents with hyperleukocytosis (ap-
proximately 40% in children vs 20%-25% in adults).88 Information
on the long-term health status of children treated with ATRA and
anthracycline-based chemotherapy is still scarce. As far as we
know, only 2 relatively small pediatric series from the German-
Austrian-Swiss group81 and the European APL group,82 as well as
2 larger series from the GIMEMA83 and PETHEMA84 groups have
published therapeutic results using a standard approach. Due to
concern regarding the use of high dose of anthracyclines and their
potential long-term cardiac toxicity, some attempts to simply
reduce the exposure to these agents without any additional
treatment modification have been made. In this respect, the
preliminary analysis of the US Intergroup study of children treated
with ATRA and reduced dose intensity of anthracycline-based
chemotherapy have not been encouraging.66 It is conceivable that,
given the benefit demonstrated by the addition of ATO in adults, the
same therapeutic measure may compensate for a relatively low
dose intensity of chemotherapy in children.66 Although this strat-
egy has not been tested formally, ATO appears to be effective in
pediatric APL as well.104 Whereas in adults several attempts have
been made to use ATO-based regimens to reduce chemotherapy, as
far as we know, there is only very limited experience of this agent
in children with newly diagnosed APL.105
Although some protocols include CNS prophylaxis, at least for
patients with hyperleukocytosis, it should be noted that neither an
increased incidence of CNS relapse nor a benefit of CNS prophy-
laxis has been established in children.
To decrease the frequency of side effects associated with
induction therapy including ATRA, particularly severe headache
and pseudotumor cerebri (PTC), which are both frequently ob-
served in children, most investigators have used a reduced dose of
ATRA (eg, 25 mg/m2 instead of 45 mg/m2) in the pediatric age
group.81-84 In this respect, the study by Castaigne et al106 showed no
difference in terms of pharmacokinetics, therapeutic efficacy,
triggering of hyperleukocytosis, or retinoic acid syndrome with
ATRA at 25 mg/m2 per day compared with the standard dose of
45 mg/m2 per day. The apparently lower incidence of PTC and
headache, together with the excellent therapeutic results obtained
with this reduced dose, suggests that 25 mg/m2 per day is recom-
mended as the standard dose in children and adolescents (see
section 5.2.1, “Induction therapy”). Because headache is common
during ATRA therapy, it is important to distinguish its etiology
including PTC, CNS leukemia, or bleeding. The diagnosis of PTC
is based on increased intracranial pressure with normal cerebrospi-
nal fluid (CSF) composition and negative cerebral imaging studies
(ie, computed tomography or magnetic resonance imaging scan). It
is usually accompanied by papilledema, but this is not a require-
ment for the diagnosis of PTC.107 In this situation, sustained
elevations in CSF pressure should be documented through succes-
sive lumbar punctures or by prolonged intracranial pressure
monitoring, if necessary.108 Sometimes, the symptoms of PTC
resolve with the initial “diagnostic” lumbar puncture. If this occurs,
no further medical treatment is required. If symptoms persist,
temporary discontinuation or dose reduction of ATRA, analgesics,
and administration of steroids and acetazolamide are the mainstays
of the medical treatment of PTC. Acetazolamide is administered in
initial doses of 25 mg/kg per day and the dose titrated upward until
clinical response is attained (maximum dose 100 mg/kg per day).
Electrolytes must be monitored to evaluate for the development of
hypokalemia and acidosis. If acetazolamide is ineffective, then
prednisone can be given at a dose of 2 mg/kg per day for 2 weeks
followed by a 2-week taper.109
6.4. Pregnant women
The incidence of APL during pregnancy is not well established and
most published data are based on case reports or very small series,
but it is accepted that it is infrequent. When it occurs, it is a
challenging situation, that nevertheless carries a high chance of
successful outcome for mother and baby after a decision-making
process that requires the involvement of the patient, hematologist,
obstetrician, and neonatologist, as was recently emphasized in the
guidelines on the management of AML in the United Kingdom.15 It
is important to highlight that any delay in starting treatment can
compromise the chance of successful remission in AML; this is
particularly true in APL, which is considered a medical emergency.
Apart from other considerations, given the teratogenic potential of
chemotherapy, ATRA, and ATO on the fetus, the most important
factors in helping to come to a decision are the gestational age and
the attitude of the patient to risk, both for herself and the fetus. For
practical purposes, in these guidelines we will address separately
the management of APL in pregnant women presenting during the
first trimester from disease arising during the second or third
trimester.
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6.4.1. Management of APL during the first trimester of
pregnancy. Given the teratogenic potential of chemotherapy,
ATRA and arsenic trioxide on the fetus, therapeutic options for
patients diagnosed during the first trimester are extremely limited
in terms of the chance of successful outcome for the fetus.
Although specific information regarding teratogenicity of ATRA is
lacking, this agent is considered highly teratogenic, certainly
because this side effect has been clearly demonstrated with other
retinoids and particularly with the closely related isotretinoin.110 As
a result, ATRA should be avoided during the first trimester.
Administration of chemotherapy during the first trimester, although
frequently safe, is also associated with fetal malformations, in-
creased risk of abortion, and low birth weight.111 Therefore, the
crucial decision in a patient with APL during the first trimester is
whether to continue with the pregnancy and receive anthracycline
chemotherapy alone or commit to terminate the pregnancy once the
patient is hemodynamically stable, in which case conventional
treatment with ATRA and chemotherapy can be commenced
immediately. If elective abortion is unacceptable, administration of
chemotherapy alone, without ATRA, would be the only reasonable
option that can be offered during the first trimester. There is some
limited evidence that idarubicin, which is more lipophilic than
other anthracyclines, favoring increased placental transfer, might
be more toxic in pregnancy.112 For this reason, it has been
suggested that daunorubicin might be preferred because this agent
is known to be effective in APL and there is more published
experience of its use in pregnancy.111 It should be noted that in case
of using chemotherapy alone, there will be an increased risk of
hemorrhage due to release of procoagulants and plasminogen
activators from malignant promyelocytes. If remission is achieved
with chemotherapy and the pregnancy is progressing normally,
treatment with ATRA could be administered later during the second
and third trimesters. The administration of additional courses of
chemotherapy during the second and third trimesters will be
discussed below.
Regarding ATO, given its high potential embryotoxicity, it
cannot be recommended for use at any stage of pregnancy. In fact,
as far as we know, this agent has not been used in pregnant humans
with APL, probably because it has been shown to be highly
embryotoxic in several animal models. Human data are limited to a
few populations exposed to arsenic (from drinking water or from
working in or living near metal smelters) in which low birth weight,
spontaneous abortion, and stillbirth are reported.113
Female patients with APL treated conventionally should be
routinely advised against conceiving while exposed to ATRA or
ATO for consolidation and maintenance therapy.
6.4.2. Management of APL during the second and third
trimesters of pregnancy. Despite the limited clinical experience,
treatment with ATRA and anthracycline-based chemotherapy seem
reasonably safe when applied to patients with APL presenting
during the second or third trimester of pregnancy. Although no
serious complications have been observed in the mother, the
considerable literature on the effect of chemotherapy on the
developing fetus, recently reviewed by Culligan and colleagues,111
suggests that chemotherapy does not cause congenital malforma-
tion, but increases the risk of abortion, prematurity, low birth
weight, neonatal neutropenia, and sepsis. For these reasons, there is
reluctance to use chemotherapy before delivery. With regard to the
administration of ATRA beyond the first trimester of pregnancy, it
is considered relatively safe for mother and fetus. Although the
experience is quite limited, there were no fetal malformations
reported suggestive of retinoic acid embryopathy.111 However,
because some cases of reversible fetal arrhythmias and other
cardiac complications at birth have been reported,114,115 stringent
fetal monitoring, with particular emphasis on cardiac function, is
recommended for patients receiving ATRA alone or combined with
chemotherapy during pregnancy.
Regarding maternal outcome after treatment with ATRA-
containing regimens, there is no evidence that this would be
different in pregnancy compared with nonpregnant patients. There-
fore, keeping in mind the aforementioned adverse effects on the
fetus of both components of treatment, ATRA and chemotherapy,
the following strategies can be outlined.
(1) Sequential use of ATRA and chemotherapy. With this
approach, patients would be treated with ATRA alone until CR,
delaying the administration of chemotherapy until after birth,
scheduled for when the fetus is deemed to be of sufficient maturity
for elective delivery. A gestational age of at least 32 weeks is
considered relatively safe when appropriate neonatal care is
provided.116 For deliveries before 36 weeks of gestation, antenatal
corticosteroids before preterm delivery are recommended to reduce
the risk of morbidity and mortality associated with respiratory
distress syndrome.117 It is assumed that vaginal delivery is associ-
ated with reduced risk of bleeding, and it is preferred (if not
contraindicated) to cesarean section, which might be required for
other reasons.111
Regarding maternal outcomes, the expected response rate with
ATRA alone is not significantly different to ATRA plus chemo-
therapy in terms of CR rate, but it can have an unfavorable impact
on the risk of relapse.52 Perhaps, this theoretical disadvantage could
be later counteracted with a reinforcement of postremission
therapy. If this strategy is followed, the administration of chemo-
therapy should not be delayed excessively to avoid resistance and
disease recurrence, which could compromise long-term outcome
for the patient. It has been suggested that molecular assessment of
response and subsequent RQ-PCR monitoring can be used to
indicate the need for introduction of chemotherapy.111 It should also
be noted that using ATRA alone there is an increased risk of APL
differentiation syndrome (approximately 25%).47
(2) Simultaneous administration of ATRA and chemotherapy.
This approach, currently considered the standard treatment for
patients in the nonpregnant state, provides the best chances of cure
and is a clear option for high-risk patients with hyperleukocytosis
and for those in which appropriate RQ-PCR monitoring is not
realistic. As previously mentioned for the management of patients
during the first trimester, daunorubicin might be preferred to
idarubicin in pregnancy, but this is not so clear for patients with
fetus in advanced gestational age.
After successful delivery, breastfeeding is contraindicated if
chemotherapy or ATO is needed. The rest of management does not
differ from other patients with APL.
6.5. Therapy-related APL
Scarce information is available about the true incidence of therapy-
related APL (tAPL) because these patients are less likely to be
entered into clinical trials and available estimates are subject to
important methodologic limitations being based on retrospective
series4,5 or the experience of single referral centers.118,119 In these
studies, tAPL cases accounted for a range from less than 5% to 22% of
all APL cases. A growing incidence of tAPL has been reported over the
last few years paralleling the increased use of topoisomerase II–targeted
drugs in both malignant and nonmalignant diseases. Breast carcinoma is
by far the most frequent previous cancer, followed by lymphoma, with a
large predominance of non-Hodgkin lymphoma compared with Hodgkin
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disease, whereas other tumor types were found with lower incidence.5
The drugs most commonly implicated in tAPL are epirubicin and
mitoxantrone, but several cases have been reported to follow exposure
to radiotherapy alone.6,120-122 Intriguingly, it has also been reported that
some cases of secondary APL (sAPL) have arisen in patients whose
primary tumor was treated by surgery without chemotherapy or
radiotherapy exposure.4,5 The latency period between chemotherapy
exposure and onset of tAPL is relatively short ( 3 years) and typically
occurs without a preceding myelodysplastic phase. Hematologic find-
ings do not differ from those observed in de novo APL, as previously
reported for other tAML with specific karyotype.123,124 However,
although the incidence of secondary chromosomal abnormalities seems
similar to that observed in de novo APL, the involvement of chromo-
somes 5, 7, or 17 appears to be more common in tAPL patients
compared with those with de novo APL.5
Regarding tAPL arising in patients treated for nonmalignant
diseases, it should be noted that since the approval by the US
Food and Drug Administration and the European Agency for
the Evaluation of Medicinal Products in 2000 of mitoxantrone
for treating aggressive forms of multiple sclerosis, cases of
tAPL have been increasingly reported.125 Review of published
case reports indicates that APL with the t(15;17) is the
predominant genetic subtype of tAML arising in this context,
with risks of developing this complication estimated at approxi-
mately 1 in 400 patients with multiple sclerosis treated with
mitoxantrone.126
Current data suggest that patients with tAPL have a relatively
favorable prognosis, although the results of one study indicated
a higher incidence of early death during treatment.5 Although a
more precise knowledge of the outcome of patients with tAPL
treated with state-of-the-art therapy should be prospectively
established, at present there is generally no reason to manage
these patients in a manner different from those with de novo
APL. However, in a significant number of patients with tAPL,
the use of conventional anthracycline-based regimens is limited
by previous anthracycline exposure and/or cardiac impairment
induced by treatment of the primary condition. In such situa-
tions, ATO in combination with ATRA provides an option for
consolidation after standard induction therapy or as first-line
treatment using schedules such as those published by the M. D.
Anderson group.75
6.6. Genetic variants of APL
Specific management of the rare genetic variants of APL cannot be
recommended because the available evidence is mostly based on
single case reports. Nevertheless, because the nature of the RARA
fusion partner can be critical to determine the response to ATRA
and ATO,127 it is reasonable that, as a general rule, patients with
ATRA-sensitive variants should be treated with standard protocols
involving ATRA combined with anthracycline-based chemo-
therapy, while those with ATRA-resistant variants should be
managed with AML-like approaches. In this regard, NuMA-RARA,
NPM1-RARA, and FIP1L1-RARA are known to be ATRA-sensitive,
while others are ATRA-resistant (STAT5b-RARA),32 relatively
resistant (PLZF-RARA), or their sensitivity to ATRA is unknown
(PRKAR1A-RARA).33 Sensitivity to ATO has not been documented
outside PML-RARA-positive APL, except for PLZF-RARA-positive
APL, which has been shown to be resistant.128
7. Management of relapse
Recommendations for the management of relapse are summarized
in Table 4.
7.1. Molecular relapse
Two studies carried out in the pre-ATO era have suggested a benefit
for preemptive therapy in patients who develop molecular relapse
compared with treatment initiated at the time of frank hematologic
relapse.94,95 The benefit of early treatment intervention remains to
be proven in the context of ATO-based relapse therapy, however the
obvious risks of hemorrhagic death and development of APL
differentiation syndrome when patients present with overt disease
argue strongly in favor of starting therapy as early as possible in
case of emergent relapse. This has provided the rationale for
sequential MRD monitoring (by every 3 months BM assessment
with assays achieving sensitivity of 1 in 104) after completion of
therapy to allow early treatment intervention. This schedule of
monitoring takes into account the maximum assay sensitivities
achievable for detection of APL fusion transcripts129 as well as the
typical kinetics of disease relapse.130 Because the majority of
relapses occur within the first 3 years after completion of consolida-
tion,131 molecular monitoring can reasonably be discontinued after
this period. The clinical utility of PB as a sample source for MRD
detection remains to be established; although good concordance
between blood and marrow PCR results has been reported during
early stages of therapy,132 analyses of paired molecular surveillance
samples taken after completion of consolidation have shown an
advantage for marrow, which on average affords 1.5-log greater
sensitivity.90,130 Recurrence of PCR positivity typically is apparent
Table 4. Management of relapse
Recommendation Level of evidence Grade of recommendation
4.1. For patients with confirmed molecular relapse (defined as 2 successive PCR-positive assays, with stable or
rising PML-RARA transcript levels detected in independent samples analyzed in 2 laboratories) preemptive
therapy has to be started promptly to prevent frank relapse.
IIa B
4.2. Although ATRA in combination with chemotherapy can be used as salvage therapy, ATO-based regimens
are presently regarded the first option for treatment of relapsed APL.
IV C
4.3. Patients achieving second CR should receive intensification with SCT or chemotherapy, if possible. IV C
4.4. Allogeneic HSCT is recommended for patients failing to achieve a second molecular remission. IV C
4.5. Autologous HSCT is a valid option for patients without detectable MRD in the marrow and with an adequate
PCR negative harvest.
IIa B
4.6. For patients in whom HSCT is not feasible, the available options include repeated cycles of ATO with or
without ATRA with or without chemotherapy.
IV C
4.7. For patients with CNS relapse, induction treatment consists of weekly triple intrathecal therapy (ITT) with
methotrexate, hydrocortisone, and cytarabine until complete clearance of blasts in the cerebrospinal fluid,
followed by 6 to 10 more spaced out ITT treatments as consolidation. Systemic treatment should also be given.
IV C
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first in the marrow, and occasionally PML-RARA transcripts do not
become detectable in PB until time of hematologic relapse.90,130
Therefore, in some patients the monitoring of PB alone (even if
performed monthly) could reduce the opportunity for successful
delivery of preemptive therapy to prevent disease progression.
Because the kinetics of disease relapse can be relatively rapid,130
preemptive therapy has to be started promptly to prevent frank
relapse. The lack of specific data about optimal management for
patients with documented molecular relapse leads us to assume a
similar strategy to that recommended for patients with visible
relapse (see section 7.2).
7.2. Hematologic relapse
Before the demonstration of the striking activity of ATO in APL,
salvage therapy usually consisted of the readministration of ATRA
and chemotherapy for induction, generally containing high-dose
cytarabine and an anthracycline, followed by further chemotherapy
and/or HSCT.95,133-135 Given the high antileukemic efficacy of ATO
in relapsed patients and its relatively favorable toxicity profile, this
agent is presently regarded as the best treatment option in this
setting.10,136 Preliminary studies with ATO as salvage therapy were
carried out by the Shanghai group in the early 1990s,137 and then
subsequently replicated in a Western population in whom the
disease had either relapsed or not responded after standard
treatment with ATRA and/or anthracycline-based chemo-
therapy.138,139 Confirmation of the high and sustained efficacy of
ATO in patients with relapsed/refractory APL has been provided by
more recent studies.140-144 CR rates in these trials were 80% to 90%
and, in those studies that evaluated survival, 50% to 70% of
patients were alive at 1 to 3 years. Current evidence suggests that
use of at least 2 cycles of ATO results in the achievement of second
molecular CR in nearly 80% of cases.145 The best consolidation
strategy after ATO induced second remission is unknown; options
include continued treatment with repeated cycles of ATO, the use of
standard chemotherapy in combination with ATRA and/or ATO,
and HSCT. While there is some evidence to suggest that treatment
intensification with HSCT146 or chemotherapy141 may improve
outcomes of patients achieving second remission with ATO,
selection of the most appropriate treatment option, as well as the
modality of HSCT, depends on a range of prognostic and logistic
variables (eg, molecular status, duration of first remission, age, donor
availability). There are no strict guidelines as regards the choice of
autologous HSCT versus allogeneic HSCT in second CR. Autologous
HSCT is obviously associated with a lower transplantation-related
mortality than allogeneic HSCT and is a reasonable option in
patients without detectable MRD and prolonged (1 year) first CR.
Allogeneic HSCT involves a greater risk of nonrelapse mortality
(transplantation-related) but offers a greater antileukemic activity
due to the graft-versus-leukemia effect. Allogeneic HSCT could be
recommended in patients failing to achieve a second molecular
remission and for those with short first CR duration.145 For patients
unfit to proceed to HSCT, the available options include repeated
cycles of ATO with or without ATRA/standard chemotherapy. In
addition, the antiCD33 monoclonal antibody conjugated to cali-
cheamicin (gemtuzumab ozogamicin) appears to induce a high rate
of molecular responses even as a single agent in advanced
disease.147,148 Therefore, although the precise role of this agent in
the management of relapsed APL remains unsettled, it should be
explored further in the treatment strategy for relapsed patients.
7.3. CNS and other extramedullary relapses
At least 1 in 10 relapses of APL have a CNS component and
therefore involvement of extramedullary sites (particularly
CNS) should be considered in patients subject to molecular or
hematologic relapse.96-98 Management of relapse in the CNS and
other extramedullary sites in patients with APL is a challenging
issue for which there is a notable lack of information. Extramed-
ullary relapse, including in the CNS, can occur either in
isolation or associated with BM involvement as a first relapse,
but also after one or more hematologic relapses. Optimal
management and outcome of APL patients in these different
situations have not been critically assessed. Relapse at extramed-
ullary sites occurs in up to 3% to 5% of patients and is emerging
as a new therapeutic issue that would need international
cooperation to prospectively evaluate treatment strategies in
sufficient numbers of cases. In the meantime, it seems pragmatic
to pursue an approach derived from experiences of the manage-
ment of extramedullary relapse in acute lymphoblastic leukemia
and other subtypes of acute myeloblastic leukemia. In this
regard, induction treatment of CNS relapse would consist of
weekly triple intrathecal therapy (ITT) with methotrexate,
hydrocortisone, and cytarabine until complete clearance of
blasts in the CSF, followed by 6 to 10 more spaced out ITT
treatments as consolidation. Because CNS disease is almost
invariably accompanied by hematologic or molecular relapse in
the marrow, systemic treatment should also be given. The timing
of this may be dictated by clinical circumstances. One approach
could be to give ATO and ATRA as a nonmyeloablative
treatment approach while ITT is being delivered. Chemotherapy
regimens with high CNS penetrance (eg, high-dose cytarabine)
have been used in this situation and in patients responding to
treatment, allogeneic or autologous transplant should be the
consolidation treatment of choice including appropriate cranio-
spinal irradiation. In case of granulocytic sarcoma, wherever it
is localized, radiation and intensive systemic therapy might be
considered.
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Appendix
Classification of evidence levels
These classifications are used in Tables 1 through 4.
Ia. Evidence obtained from meta-analysis of randomized con-
trolled trials.
Ib. Evidence obtained from at least one randomized controlled trial.
IIa. Evidence obtained from at least one well-designed con-
trolled study without randomization.
IIb. Evidence obtained from at least one other type of well-
designed quasi-experimental study.
III. Evidence obtained from well-designed nonexperimental
descriptive studies, such as comparative studies, correlation stud-
ies, and case studies.
IV. Evidence obtained from expert committee reports or opin-
ions and/or clinical experiences of respected authorities.
Classification of grades of recommendations
A. Requires at least one randomized controlled trial as part of a
body of literature of overall good quality and consistency address-
ing specific recommendation (evidence levels Ia and Ib).
B. Requires the availability of well-conducted clinical studies
but no randomized clinical trials on the topic of recommendation
(evidence levels IIa, Iib, and III).
C. Requires evidence obtained from expert committee reports
or opinions and/or clinical experiences of respected authorities.
Indicates an absence of directly applicable clinical studies of good
quality (evidence level IV).
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